Novavax Appoints Biotechnology Veteran David Mott to Board of Directors
16 juin 2020 08h00 HE
|
Novavax, Inc.
GAITHERSBURG, Md., June 16, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
Novavax to Raise $200 Million from Private Placement with RA Capital
15 juin 2020 10h09 HE
|
Novavax, Inc.
GAITHERSBURG, Md., June 15, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
Novavax President of R&D Dr. Gregory Glenn to Discuss the Development of COVID-19 Vaccines on Panel at 2020 BIO Digital
08 juin 2020 16h05 HE
|
Novavax, Inc.
GAITHERSBURG, Md., June 08, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
Novavax Awarded Department of Defense Contract for COVID-19 Vaccine
04 juin 2020 20h04 HE
|
Novavax, Inc.
$60 million funding for manufacturing of NVX-CoV237310 million doses to be delivered to DoD in 2020 GAITHERSBURG, Md., June 04, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage...
Novavax Expands Large-Scale Global Manufacturing Capacity
27 mai 2020 08h00 HE
|
Novavax, Inc.
Novavax acquires Praha Vaccines in Czech RepublicAnnual operating capacity of over 1 billion doses of COVID-19 vaccine antigen GAITHERSBURG, Md., May 27, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc....
Novavax Initiates Phase 1/2 Clinical Trial of COVID-19 Vaccine
25 mai 2020 16h30 HE
|
Novavax, Inc.
First participants enrolled in Phase 1 portion of clinical trial of NVX‑CoV2373Preliminary immunogenicity and safety results expected in July 2020Phase 2 portion to begin promptly following successful...
Novavax Reports First Quarter 2020 Financial Results
11 mai 2020 16h05 HE
|
Novavax, Inc.
CEPI increases investment up to $388 million for NVX‑CoV2373 vaccine development & manufacturingNVX‑CoV2373 Phase I trial initiating in May with preliminary results in JulyNanoFlu recently...
Novavax to Receive up to $388 Million Funding from CEPI for COVID-19 Vaccine Development and Manufacturing
11 mai 2020 16h02 HE
|
Novavax, Inc.
Funds clinical development of NVX-CoV2373 through Phase 2Supports rapid scale-up of vaccine manufacturingAllows for increased production of Matrix-M adjuvantReserves global large-scale manufacturing...
Novavax to Present COVID-19 Vaccine Candidate Progress in World Vaccine Congress Webinar Series
11 mai 2020 11h52 HE
|
Novavax, Inc.
GAITHERSBURG, Md., May 11, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 11, 2020
06 mai 2020 09h15 HE
|
Novavax, Inc.
GAITHERSBURG, Md., May 06, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...